Myelodysplastic syndromes (MDS) comprise a heterogeneous group of clonal hematopoietic stem cell malignancies with significant morbidity and high mortality. The incidence of MDS increases markedly with age, and the disease is most prevalent in individuals who are white and male. It is conservatively estimated that >10,000 new cases of MDS occur in the United States annually, and that >= 60,000 individuals with MDS currently reside in the country. With an aging population and an improving awareness of the disease, the documented disease burden is expected to escalate in the near future. Recent studies have identified new or inconsistent etiologic factors that warrant further research. Given the poor survival of individuals with MDS, it is important to identify prognostic factors to better risk-stratify patients for more effective treatment. The relevance of different comorbidities to MDS prognosis and the potential interaction between various comorbidities represents an interesting area of research. (C) 2012 Elsevier Inc. All rights reserved. . The American Journal of Medicine (2012) 125, S2-S5
机构:
Az Policlin Umberto I Sapienza Univ, Dept Translat & Precis Med, Rome, ItalyAz Policlin Umberto I Sapienza Univ, Dept Translat & Precis Med, Rome, Italy
Breccia, Massimo
Vinchi, Francesca
论文数: 0引用数: 0
h-index: 0
机构:
New York Blood Ctr, Iron Res Lab, New York, NY USA
Weill Cornell Med, Dept Pathol & Lab Med, New York, NY USAAz Policlin Umberto I Sapienza Univ, Dept Translat & Precis Med, Rome, Italy